Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 2,800,000 shares, a decline of 10.5% from the October 15th total of 3,130,000 shares. Approximately 13.2% of the company's stock are sold short. Based on an average daily trading volume, of 393,300 shares, the days-to-cover ratio is currently 7.1 days.

Hedge Funds Weigh In On Agenus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company's stock valued at $19,953,000 after purchasing an additional 4,134,232 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Agenus by 1,959.9% in the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company's stock worth $439,000 after buying an additional 720,629 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company's stock worth $2,648,000 after buying an additional 32,016 shares during the last quarter. State Street Corp raised its holdings in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company's stock valued at $2,563,000 after acquiring an additional 9,731 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company's stock valued at $208,000 after acquiring an additional 123,058 shares during the last quarter. Institutional investors and hedge funds own 61.46% of the company's stock.

Agenus Price Performance

AGEN stock traded down $0.05 during trading on Friday, reaching $2.72. 1,073,463 shares of the stock traded hands, compared to its average volume of 482,718. Agenus has a 52-week low of $2.58 and a 52-week high of $19.69. The business's 50 day moving average price is $4.70 and its 200-day moving average price is $8.67.

Analysts Set New Price Targets

A number of research firms recently commented on AGEN. StockNews.com downgraded shares of Agenus from a "hold" rating to a "sell" rating in a research report on Monday, August 12th. HC Wainwright reduced their target price on Agenus from $8.00 to $7.00 and set a "neutral" rating for the company in a report on Tuesday, November 12th. Finally, B. Riley dropped their target price on shares of Agenus from $42.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, Agenus currently has an average rating of "Hold" and an average price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.